Clinical Scales of Cerebellar Ataxias

Abstract

The development, evaluation, and validation of new clinical scales for the assessment of disease severity and progression in cerebellar disease have gained increasing impact during the last years. Currently, there are four different scales that are most frequently applied: The International Cooperative Ataxia Rating Scale (ICARS), the Brief Ataxia Rating Scale (BARS), the Friedreich Ataxia Rating Scale (FARS), and the Scale for the Assessment and Rating of Ataxia (SARA). All scales have been validated and compared with regard to their testing properties. It has been shown that each scale has its strengths and weaknesses. It is therefore important to carefully select the clinical scale when preparing a clinical or therapeutic study. It is also important to note that the quality of a rating scale is not only defined by its interrater reliability and construct validity but also by its user friendliness. A scale’s compactness guarantees attractiveness to the clinician, reduces expenditure of time and money, and will thereby alleviate further clinical trials. Large, elaborated scales are certainly useful for thorough documentation of specific features of certain phenotypes, but this gain of information is not always essential for the purpose of a study. It is therefore no surprise that short and manageable scales like SARA are often preferred to more elaborated scales in observational and therapeutic studies.

Keywords

Multiple System Atrophy Barthel Index Functional Independence Measure Kinetic Function International Cooperative Ataxia Rate Scale 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

References

  1. Artuch R, Aracil A, Mas A, Colome C, Rissech M, Monros E, Pineda M (2002) Friedreich’s ataxia: idebenone treatment in early stage patients. Neuropediatrics 33:190–193PubMedCrossRefGoogle Scholar
  2. Bier JC, Dethy S, Hildebrand J, Jacquy J, Manto M, Martin JJ, Seeldrayers P (2003) Effects of the oral form of ondansetron on cerebellar dysfunction. A multi-center double-blind study. J Neurol 250:693–697PubMedCrossRefGoogle Scholar
  3. Boesch S, Sturm B, Hering S, Goldenberg H, Poewe W, Scheiber-Mojdehkar B (2007) Friedreich’s ataxia: clinical pilot trial with recombinant human erythropoietin. Ann Neurol 62:521–524PubMedCrossRefGoogle Scholar
  4. Bradley JL, Homayoun S, Hart PE, Schapira AH, Cooper JM (2004) Role of oxidative damage in Friedreich’s ataxia. Neurochem Res 29:561–567PubMedCrossRefGoogle Scholar
  5. Broccoletti T, Del Giudice E, Cirillo E, Vigliano I, Giardino G, Ginocchio VM, Bruscoli S, Riccardi C, Pignata C (2011) Efficacy of very-low-dose betamethasone on neurological symptoms in ataxia-telangiectasia. Eur J Neurol 18:564–570PubMedCrossRefGoogle Scholar
  6. Bürk K, Malzig U, Wolf S, Heck S, Dimitriadis K, Schmitz-Hubsch T, Hering S, Lindig TM, Haug V, Timmann D, Degen I, Kruse B, Dorr JM, Ratzka S, Ivo A, Schols L, Boesch S, Klockgether T, Klopstock T, Schulz JB (2009) Comparison of three clinical rating scales in Friedreich ataxia (FRDA). Mov Disord 24:1779–1784PubMedCrossRefGoogle Scholar
  7. Cano SJ, Hobart JC, Hart PE, Korlipara LV, Schapira AH, Cooper JM (2005) International Cooperative Ataxia Rating Scale (ICARS): appropriate for studies of Friedreich’s ataxia? Mov Disord 20:1585–1591PubMedCrossRefGoogle Scholar
  8. Cooper JM, Korlipara LV, Hart PE, Bradley JL, Schapira AH (2008) Coenzyme Q10 and vitamin E deficiency in Friedreich’s ataxia: predictor of efficacy of vitamin E and coenzyme Q10 therapy. Eur J Neurol 15:1371–1379PubMedCrossRefGoogle Scholar
  9. Di Prospero NA, Baker A, Jeffries N, Fischbeck KH (2007) Neurological effects of high-dose idebenone in patients with Friedreich’s ataxia: a randomised, placebo-controlled trial. Lancet Neurol 6:878–886PubMedCrossRefGoogle Scholar
  10. Fahey MC, Corben L, Collins V, Churchyard AJ, Delatycki MB (2007) How is disease progress in Friedreich’s ataxia best measured? A study of four rating scales. J Neurol Neurosurg Psychiatry 78:411–413PubMedCrossRefGoogle Scholar
  11. Gazulla J, Benavente I (2007) Single-blind, placebo-controlled pilot study of pregabalin for ataxia in cortical cerebellar atrophy. Acta Neurol Scand 116:235–238PubMedCrossRefGoogle Scholar
  12. Goetz CG, Stebbins GT, Chmura TA, Fahn S, Klawans HL, Marsden CD (1995) Teaching tape for the motor section of the unified Parkinson’s disease rating scale. Mov Disord 10:263–266PubMedCrossRefGoogle Scholar
  13. Goetz CG, Tilley BC, Shaftman SR, Stebbins GT, Fahn S, Martinez-Martin P, Poewe W, Sampaio C, Stern MB, Dodel R, Dubois B, Holloway R, Jankovic J, Kulisevsky J, Lang AE, Lees A, Leurgans S, LeWitt PA, Nyenhuis D, Olanow CW, Rascol O, Schrag A, Teresi JA, van Hilten JJ, LaPelle N (2008) Movement Disorder Society-sponsored revision of the Unified Parkinson’s Disease Rating Scale (MDS-UPDRS): scale presentation and clinimetric testing results. Mov Disord 23:2129–2170PubMedCrossRefGoogle Scholar
  14. Heo JH, Lee ST, Chu K, Kim M (2008) The efficacy of combined estrogen and buspirone treatment in olivopontocerebellar atrophy. J Neurol Sci 271:87–90PubMedCrossRefGoogle Scholar
  15. Huntington Study Group (1996) Unified Huntington’s Disease Rating Scale: reliability and consistency. Mov Disord 11:136–142CrossRefGoogle Scholar
  16. Kearney M, Orrell RW, Fahey M, Pandolfo M (2009) Antioxidants and other pharmacological treatments for Friedreich ataxia. Cochrane Database Syst Rev 4:CD007791PubMedGoogle Scholar
  17. Keith RA, Granger CV, Hamilton BB, Sherwin FS (1987) The functional independence measure: a new tool for rehabilitation. Adv Clin Rehabil 1:6–18PubMedGoogle Scholar
  18. Kimura N, Kumamoto T, Masuda T, Nomura Y, Hanaoka T, Hazama Y, Okazaki T, Arakawa R (2009) Evaluation of the effect of thyrotropin releasing hormone (TRH) on regional cerebral blood flow in spinocerebellar degeneration using 3DSRT. J Neurol Sci 281:93–98PubMedCrossRefGoogle Scholar
  19. Kimura N, Kumamoto T, Masuda T, Nomura Y, Hanaoka T, Hazama Y, Okazaki T (2011) Evaluation of the effects of Thyrotropin Releasing Hormone (TRH) therapy on regional cerebral blood flow in the cerebellar variant of multiple system atrophy using 3DSRT. J Neuroimaging 21:132–137PubMedCrossRefGoogle Scholar
  20. Klockgether T, Lüdtke R, Kramer B, Abele M, Bürk K, Schöls L, Riess O, Laccone F, Boesch S, Lopes-Cendes I, Brice A, Inzelberg R, Zilber N, Dichgans J (1998) The natural history of degenerative ataxia: a retrospective study in 466 patients. Brain 121(Pt 4):589–600PubMedCrossRefGoogle Scholar
  21. Lohle M, Schrempf W, Wolz M, Reichmann H, Storch A (2008) Potassium channel blocker 4-aminopyridine is effective in interictal cerebellar symptoms in episodic ataxia type 2–a video case report. Mov Disord 23:1314–1316PubMedCrossRefGoogle Scholar
  22. Lynch DR, Perlman SL, Meier T (2010) A phase 3, double-blind, placebo-controlled trial of idebenone in friedreich ataxia. Arch Neurol 67:941–947PubMedCrossRefGoogle Scholar
  23. Mori M, Adachi Y, Mori N, Kurihara S, Kashiwaya Y, Kusumi M, Takeshima T, Nakashima K (2002) Double-blind crossover study of branched-chain amino acid therapy in patients with spinocerebellar degeneration. J Neurol Sci 195:149–152PubMedCrossRefGoogle Scholar
  24. Nakamura K, Yoshida K, Miyazaki D, Morita H, Ikeda S (2009) Spinocerebellar ataxia type 6 (SCA6): clinical pilot trial with gabapentin. J Neurol Sci 278:107–111PubMedCrossRefGoogle Scholar
  25. Pineda M, Arpa J, Montero R, Aracil A, Dominguez F, Galvan M, Mas A, Martorell L, Sierra C, Brandi N, Garcia-Arumi E, Rissech M, Velasco D, Costa JA, Artuch R (2008) Idebenone treatment in paediatric and adult patients with Friedreich ataxia: long-term follow-up. Eur J Paediatr Neurol 12:470–475PubMedCrossRefGoogle Scholar
  26. Pineda M, Montero R, Aracil A, O’Callaghan MM, Mas A, Espinos C, Martinez-Rubio D, Palau F, Navas P, Briones P, Artuch R (2010) Coenzyme Q(10)-responsive ataxia: 2-year-treatment follow-up. Mov Disord 25:1262–1268PubMedCrossRefGoogle Scholar
  27. Ristori G, Romano S, Visconti A, Cannoni S, Spadaro M, Frontali M, Pontieri FE, Vanacore N, Salvetti M (2010) Riluzole in cerebellar ataxia: a randomized, double-blind, placebo-controlled pilot trial. Neurology 74:839–845PubMedCrossRefGoogle Scholar
  28. Schmahmann JD, Gardner R, MacMore J, Vangel MG (2009) Development of a brief ataxia rating scale (BARS) based on a modified form of the ICARS. Mov Disord 24:1820–1828PubMedCrossRefGoogle Scholar
  29. Schmitz-Hübsch T, du Tezenas MS, Baliko L, Boesch S, Bonato S, Fancellu R, Giunti P, Globas C, Kang JS, Kremer B, Mariotti C, Melegh B, Rakowicz M, Rola R, Romano S, Schols L, Szymanski S, van de Warrenburg BP, Zdzienicka E, Durr A, Klockgether T (2006a) Reliability and validity of the International Cooperative Ataxia Rating Scale: a study in 156 spinocerebellar ataxia patients. Mov Disord 21:699–704PubMedCrossRefGoogle Scholar
  30. Schmitz-Hübsch T, du Montcel ST, Baliko L, Berciano J, Boesch S, Depondt C, Giunti P, Globas C, Infante J, Kang JS, Kremer B, Mariotti C, Melegh B, Pandolfo M, Rakowicz M, Ribai P, Rola R, Schols L, Szymanski S, van de Warrenburg BP, Durr A, Klockgether T, Fancellu R (2006b) Scale for the assessment and rating of ataxia: development of a new clinical scale. Neurology 66:1717–1720PubMedCrossRefGoogle Scholar
  31. Schmitz-Hübsch T, Coudert M, Bauer P, Giunti P, Globas C, Baliko L, Filla A, Mariotti C, Rakowicz M, Charles P, Ribai P, Szymanski S, Infante J, van de Warrenburg BP, Durr A, Timmann D, Boesch S, Fancellu R, Rola R, Depondt C, Schöls L, Zdienicka E, Kang JS, Döhlinger S, Kremer B, Stephenson DA, Melegh B, Pandolfo M, Di Donato S, du Montcel ST, Klockgether T (2008a) Spinocerebellar ataxia types 1, 2, 3, and 6: disease severity and nonataxia symptoms. Neurology 71:982–989PubMedCrossRefGoogle Scholar
  32. Schmitz-Hübsch T, Giunti P, Stephenson DA, Globas C, Baliko L, Sacca F, Mariotti C, Rakowicz M, Szymanski S, Infante J, van de Warrenburg BP, Timmann D, Fancellu R, Rola R, Depondt C, Schöls L, Zdzienicka E, Kang JS, Döhlinger S, Kremer B, Melegh B, Filla A, Klockgether T (2008b) SCA Functional Index: a useful compound performance measure for spinocerebellar ataxia. Neurology 71:486–492PubMedCrossRefGoogle Scholar
  33. Schmitz-Hübsch T, Fimmers R, Rakowicz M, Rola R, Zdzienicka E, Fancellu R, Mariotti C, Linnemann C, Schöls L, Timmann D, Filla A, Salvatore E, Infante J, Giunti P, Labrum R, Kremer B, van de Warrenburg BP, Baliko L, Melegh B, Depondt C, Schulz J, du Montcel ST, Klockgether T (2010) Responsiveness of different rating instruments in spinocerebellar ataxia patients. Neurology 74:678–684PubMedCrossRefGoogle Scholar
  34. Shah S, Vanclay F, Cooper B (1989) Improving the sensitivity of the Barthel Index for stroke rehabilitation. J Clin Epidemiol 42:703–709PubMedCrossRefGoogle Scholar
  35. Storey E, Tuck K, Hester R, Hughes A, Churchyard A (2004) Inter-rater reliability of the International Cooperative Ataxia Rating Scale (ICARS). Mov Disord 19:190–192PubMedCrossRefGoogle Scholar
  36. Subramony SH, May W, Lynch D, Gomez C, Fischbeck K, Hallett M, Taylor P, Wilson R, Ashizawa T (2005) Measuring Friedreich ataxia: interrater reliability of a neurologic rating scale. Neurology 64:1261–1262PubMedCrossRefGoogle Scholar
  37. Weyer A, Abele M, Schmitz-Hübsch T, Schoch B, Frings M, Timmann D, Klockgether T (2007) Reliability and validity of the scale for the assessment and rating of ataxia: a study in 64 ataxia patients. Mov Disord 22:1633–1637PubMedCrossRefGoogle Scholar
  38. Yabe I, Matsushima M, Soma H, Basri R, Sasaki H (2008) Usefulness of the Scale for Assessment and Rating of Ataxia (SARA). J Neurol Sci 266:164–166PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media Dordrecht 2013

Authors and Affiliations

  1. 1.Department of NeurologyPhilipps University of MarburgMarburgGermany

Personalised recommendations